Celestia S. Higano
Pulmonary and Respiratory Medicine · 2006–2019
A researcher in the Science corpus: 18 papers; trusts 2 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 132 citations into it; #635 of 770 by trust here, #38 by citations
- Immunology — 18 citations into it
Whom Celestia S. Higano trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Celestia S. Higano overall
Papers from Celestia S. Higano's perspective
Ordered by how strongly the researchers Celestia S. Higano trusts endorse each paper. Same corpus, a different order for every researcher.
- Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (American Journal of Pathology)
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
- Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (Cancer Research)
- Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)
- Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (Journal of the National Cancer Institute)
- A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. (Journal of the National Cancer Institute)
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (New England Journal of Medicine)
- Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. (Journal of Clinical Oncology)
- Mechanisms and functional significance of tumour-induced dendritic-cell defects (Nature reviews. Immunology)
Their papers
- Quantitative and stoichiometric analysis of the microRNA content of exosomes (2014) — 1,020 citations
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B (2012) — 772 citations
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) — 1,328 citations
- Prostate Cancer, Version 1.2016. (2016) — 642 citations
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) — 1,381 citations
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. (2015) — 1,271 citations
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (2014) — 2,782 citations
- Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy (2012) — 902 citations
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine (2011) — 672 citations
- Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) — 5,378 citations
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study (2010) — 1,043 citations
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer (2009) — 2,232 citations
- Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009) — 845 citations
- Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. (2008) — 1,429 citations
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) — 2,212 citations
- Guideline for the management of clinically localized prostate cancer: 2007 update. (2007) — 1,213 citations
- Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. (2007) — 852 citations
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. (2006) — 1,121 citations